| Literature DB >> 30104810 |
Jorge Sanchez1,2, Andres Sánchez1,3, Ricardo Cardona1.
Abstract
BACKGROUND: Epidemiological studies have shown that children who grow up on traditional farms are protected from allergic diseases. However, less is known about if the environment influences the pharmacotherapy in these patients.Entities:
Keywords: Asthma; children; diagnosis; rhinitis; rural; treatment; urban
Mesh:
Substances:
Year: 2018 PMID: 30104810 PMCID: PMC6084920 DOI: 10.25100/cm.v49i2.3015
Source DB: PubMed Journal: Colomb Med (Cali) ISSN: 0120-8322
Pharmacotherapy points according GINA steps. 2 times for week 1 point
| GINA step | First Choice | Second Choice | Score |
|---|---|---|---|
| Step 1 | No need continuous control therapy | 0 point | |
| low dose ICS <2 times for week.- SABA >2 times for week | 1 point | ||
| Step 2 | Low dose ICS | LTRA. Low dose theophyline | 2 points |
| Step 3 | Low dose ICS/LABA | Medium dose of ICS dose | 3 points |
| High dose of ICS dose. - Low dose ICS/LABA +LTRA (or +theophylline) | 4 points | ||
| Step 4 | Medium dose of ICS | 4 points | |
| Step 5 | Tiotropium*. - Omalizumab - Mepoluzumab | 6 points | |
| Add low dose OCS | 7 points |
LTRA: Leukotriene receptor antagonists. SABA: Short-acting beta2-agonist; ICS: inhaled corticosteroids; OCS: Oral corticosteroids; LABA: long-acting beta2-agonist; med: medium dose; OCS: oral corticosteroids
Low, medium, and high dose of the different ICS was defined according to GINA guideline. Tiotropium was only for children over 12 years.
Pharmacotherapy points according ARIA steps.
| ARIA step | First Choice | Second Choice | Score |
|---|---|---|---|
| Mild intermittent | Oral anti-H1 intermittent (<2 days per week) | Intra-nasal or oral decongestant (<10 days per month) | 0 point |
| Oral anti-H1 intermittent (>3 days per week) | 1 point | ||
| Moderate/severe Intermittent | Intra-nasal steroid | Local chromone | 2 points |
| Mild persistent | Intra-nasal steroid and antiH1 | Intra-nasal-steroid and AntiL | 3 points |
| Moderate/severe Persistent | Intra-nasal steroid + antiH1 + antiL | 4 points |
AntiH1: Antihistamine
Figure 1The flow chart represent the different moments of the study and the interventions during each step. ACT: Asthma Control Test. ARSQ: Allergy Rhinitis Symptoms Control.
Socio-demographics characteristics.
| Socio-demographics characteristics | Rural n (%) | Urban n (%) |
|
|---|---|---|---|
| Population n= 382 | 134 (35.1) | 248 (64.9) | >0.10 |
| Males n= 236 (61.7%) | 80 (59.7) | 156 (62.9) | >0.10 |
| Age mean (range) | 8 (6-14 SD: 4) | 7 (6-14 SD: 5) | >0.10 |
| Asthma | 80 (59.7) | 186 (75) | 0.07 |
| Rhinitis | 112 (83.5) | 224 (90.3) | 0.09 |
| Atopy | 329 (86.1) | 351 (91.8) | 0.07 |
| Natural Gas | 120 (89.5) | 234 (94.3) | >0.10 |
| Electricity | 124 (92.5) | 248 (100.0) | 0.08 |
| Trash burning at home | 24 (19.3) | 10 (4) |
|
| Passive exposure to trash | 28 (20.8) | 20 (8) |
|
| Tap water | 124 (92.5) | 238 (95.9) | >0.10 |
| Sewage | 112 (83.5) | 351 (91.8) | 0.08 |
| Houses of material | 120 (89.5) | 238 (95.9) | 0.09 |
| Covered floor | 114 (85.0) | 234 (94.3) | 0.06 |
| Socioeconomic strata (low 1 to 3) | 130 (97.0) | 218 (87.9) |
|
| ACT baseline | 18 (2-27 SD: 8) | 15 (2-27 SD: 14) | 0.06 |
| ARSQ baseline | 12 (0-28 SD: 7) | 16 (0-28 SD: 12) |
|
ACT: Asthma Control Test.
ARSQ: Allergy Rhinitis Symptoms Control.
p <0.05 was statistically significant
The percentages are presented in parentheses
SD: Standard deviation
Figure 2Percent of control according ACT and ARSQ are presented. ACT: Asthma Control Test. ARSQ: Allergy Rhinitis symptoms Control. P <0.05 was statistically significant.
Bronchial symptoms and spirometry.
| Rural n= 80 (59.7 %) | Urban n= 186 (75 %) | p | |
|---|---|---|---|
| Days with Salbutamol per month: baseline/12months | 4.8/2.4 (-50) | 6.3/4.5 (-28.5) | 0.01 |
| Days in Emergency department: baseline/12months | 1.4/0.4 (-71.4) | 1.8/0.8 (-55.6) | <0.01 |
| Baseline FEV1 (% predicted) | 87+14 | 84+17 | >0.10 |
| Baseline FEV1<80% no. (%) | 8 (10.0) | 26 (13.9) |
|
| Baseline FEV1/FVC ratio | 86.0 + 13.4 | 81.0 + 10.4 | >0.10 |
| 1 year FEV1 (% predicted) | 91.0 + 14.0 | 86.4+15.0 | 0.07 |
| 1 year FEV1<80% no. (%) | 2.0 (2.5) | 20.0 (10.7) |
|
| 1 year FEV1/FVC ratio | 88.0 + 13.4 | 85.0 + 10.4 | >0.10 |
Spirometry was done at the beginning and after 12 months. Salbutamol and emergency department frequency was obtained in the first and the last medical visit.
The percentages are presented in parentheses
Figure 3Comparison of pharmacotherapy score in asthma (Figure 3A) and rhinitis (Figure 3B). Changes in the pharmacotherapy during time (Baseline vs 12 months) and groups (Rural vs Urban) were compared. The percent numbers represent modifications in pharmacotherapy: negative values represent a reduction. p <0.05 was statistically
Puntos de farmacoterapia de acuerdo a los pasos GINA. 2 veces por semanda 1 punto
| Pasos GINA | Primera opción | Segunda opción | Puntaje |
|---|---|---|---|
| Paso 1 | No necesita una terapia de control continua | 0 puntos | |
| Baja dosis ICS <2 veces por semana - SABA >2 veces por semana | 1 punto | ||
| Paso 2 | Dosis baja de ICS | LTRA. Dosis baja de theophyline | 2 puntos |
| Paso 3 | Baja dosis de ICS/LABA | Dosis media de ICS | 3 puntos |
| Dosis alta de ICS. - Dosis baja de ICS/LABA +LTRA (o +theophylline) | 4 puntos | ||
| Paso 4 | Dosis media de ICS | 4 puntos | |
| Paso 5 | Tiotropium*. - Omalizumab - Mepoluzumab | 6 puntos | |
| Adicione una disis baja de OCS | 7 puntos |
LTRA: Receptor antagonista de Leukotriene. SABA: Short-acting beta2-agonist; ICS: Corticosteroides inhalados; OCS: Corticosteroides orales; LABA: long-acting beta2-agonist; OCS: Oral corticosteroids
Las dosis baja, media y alta ICS fueron definidas de acuerdo a la guia GINA. Tiotropium se dio solo para niños >12 años.
Puntos de farmacoterapia de acuerdo a los pasos ARIA.
| Pasos ARIA | Primera opción | Segunda opción | Puntaje |
|---|---|---|---|
| Leve intermitente | Anti-H1 intermitente oral (<2 veces por semana) | Decongestionante intra-nasal u oral (<10 dias por mes) | 0 puntos |
| Anti-H1 intermitente oral (>3 dias por semana) | 1 punto | ||
| Moderada/severa intermitente | Esteroides intra-nasal | Cromona local | 2 puntos |
| Leve persistente | Esteroides intra-nasal y antiH1 | Esteroides intra-nasal- y AntiL | 3 puntos |
| Moderada/severa persistente | Esteroides intra-nasal + antiH1 + antiL | 4 puntos |
AntiH1: Antihistamina
Figura 1El diagrama de flujo representa los diferentes momentos del estudio y las intervenciones durante cada paso. ACT: prueba de control del asma. ARSQ: Control de los síntomas de la rinitis alérgica.
Características Socio-demográficas.
| Características Socio-demográficas | Rural n (%) | Urbano n (%) | |
|---|---|---|---|
| Población n= 382 | 134 (35.1) | 248 (64.9) | >0.1 |
| Hombres n= 236, 61.7% | 80 (59.7) | 156 (62.9) | >0.1 |
| Edad media (rango) | 8 (6-14 SD 4) | 7 (6-14 SD 5) | >0.1 |
| Asma | 80 (59.7) | 186 (75) | 0.07 |
| Rinitis | 112 (83.5) | 224 (90.3) | 0.09 |
| Atopia | 329 (86.1) | 351 (91.8) | 0.07 |
| Gas natural | 120 (89.5) | 234 (94.3) | >0.1 |
| Electricidad | 124 (92.5) | 248 (100) | 0.08 |
| Basura quemada en casa | 24 (19.3) | 10 (4) | |
| Exposición pasiva a basuras | 28 (20.8) | 20 (8) | |
| Agua de grifo | 124 (92.5) | 238 (95.9) | >0.1 |
| Aguas residuales | 112 (83.5) | 351 (91.8) | 0.08 |
| Casas de material | 120 (89.5) | 238 (95.9) | 0.09 |
| Piso cubierto | 114 (85.0) | 234 (94.3) | 0.06 |
| Estrato Socioeconómico (1 a 3) | 130 (97.0) | 218 (87.9) | |
| ACT basal | 18 (2-27 DE: 8) | 15 (2-27 DE: 14) | 0.06 |
| ARSQ basal | 12 (0-28 DE: 7) | 16 (0-28 DE: 12) |
ACT: prueba de control del asma.
ARSQ: Control de los síntomas de la rinitis alérgica.
Una p <0.05 fue estadísticamente significativo
Los porcentajes se presentan entre paréntesis
DE: Desviación estándar
Figura 2Porcentaje de control de acuerdo a ACT y ARSQ. ACT: prueba de control del asma. ARSQ: Control de los síntomas de la rinitis alérgica. La p <0.05 fue estadísticamente significativa.
Exacerbaciones y función pulmonar.
| Rural n= 80 (59.7%) | Urbano n= 186 (75%) | p | |
|---|---|---|---|
| Días con salbutamol por mes: Inicial/12 meses | 4.8/2.4 (-50) | 6.3/4.5 (-28.5) | 0.01 |
| Días en departamento de urgencias: Inicial/12 meses | 1.4/0.4 (-71.4) | 1.8/0.8 (-55.6) | <0.01 |
| Inicial FEV1 (% predictivo) | 87+14 | 84+17 | >0.1 |
| Inicial FEV1 <80% no. (%) | 8 (10.0) | 26 (13.9) | |
| Inicial FEV1/FVC radio | 86 + 13.4 | 81 + 10.4 | >0.1 |
| 1 año FEV1 (% predictivo) | 91 + 14 | 86,4+15 | 0.07 |
| 1 año FEV1<80% no. (%) | 2 (2.5) | 20 (10.7) | |
| 1 año FEV1/FVC radio | 88 + 13.4 | 85 + 10.4 | >0.1 |
La espirometría se realizó al comienzo y después de 12 meses. El uso de salbutamol y la frecuencia de asistencia al servicio a urgencias se obtuvieron en la primera y la última consulta médica.
Los porcentajes se presentan entre paréntesis
Figura 3Comparación de la puntuación de farmacoterapia en el asma (A) y la rinitis (B). Se compararon los cambios en la farmacoterapia a lo largo del tiempo (inicial versus 12 meses) y grupos (rural versus urbano). Los porcentajes representan modificaciones en la farmacoterapia: los valores negativos representan una reducción. La p <0.05 fue estadísticamente significativa.